, Volume 22, Issue 7, pp 478–478 | Cite as

Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors’ Reply

  • Sean D. Sullivan
  • Kavita Patel
  • Jesse Green


Major Public Health Concern Simulated Population Incremental Benefit Fibrosis Progression Male Cohort 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003 Jul; 290 (2): 228–37PubMedCrossRefGoogle Scholar
  2. 2.
    Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: riles, benefits, costs. JAMA 1998; 280: 2088–93PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Sean D. Sullivan
    • 1
  • Kavita Patel
    • 2
  • Jesse Green
    • 2
  1. 1.University of WashingtonSeattleUSA
  2. 2.RocheNutleyUSA

Personalised recommendations